Last reviewed · How we verify
Pegylated Interferon, Ribavirin, Boceprevir
This triple-drug combination inhibits hepatitis C virus replication by boosting interferon-mediated antiviral immunity, blocking viral RNA synthesis, and directly inhibiting the NS3/4A protease.
This triple-drug combination inhibits hepatitis C virus replication by boosting interferon-mediated antiviral immunity, blocking viral RNA synthesis, and directly inhibiting the NS3/4A protease. Used for Chronic hepatitis C virus infection (genotype 1).
At a glance
| Generic name | Pegylated Interferon, Ribavirin, Boceprevir |
|---|---|
| Also known as | PEG IFN alfa 2b : Peg Intron, Ribavirin: Rebetol, Boceprevir: Victrelis |
| Sponsor | University of Modena and Reggio Emilia |
| Drug class | Antiviral combination therapy (interferon + nucleoside analog + protease inhibitor) |
| Target | HCV NS3/4A protease, HCV RNA polymerase, interferon signaling pathway |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
Pegylated interferon stimulates the innate immune system to attack HCV-infected cells. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and reduces viral mutation rates. Boceprevir is a direct-acting antiviral that specifically inhibits the HCV NS3/4A serine protease, which is essential for viral polyprotein processing and replication.
Approved indications
- Chronic hepatitis C virus infection (genotype 1)
Common side effects
- Anemia
- Fatigue
- Headache
- Nausea
- Dysgeusia (taste disturbance)
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
Key clinical trials
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection (PHASE3)
- The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) (PHASE3)
- Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) (PHASE3)
- Impact of Antiviral Therapy on Gastroesophageal Varices.
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) (PHASE2)
- Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) (PHASE3)
- An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
- Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: